Phosphorus Metabolism in Neoplastic Tissue.

Erf, Lowell A.; Lawrence, John H.

doi:10.3181/00379727-46-13009p

Cited by 24 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The amount of activity retained in the injection locality represents here the uptake of phosphorus activity by normal tissues. This ratio is supposed to increase in the case of tumour tissues, as it is well known that there is a greater retention of radiophosphorus by experimental animals and patients who have neoplastic diseases [8][9][10] than among normal animals or persons. Also, it has been shown that the rapidly growing tissues absorb and retain a. higher proportion of the radiophosphorus than comparable normal tissues in the first few days after administration.…”

Section: Discussionmentioning

confidence: 99%

Part III: Study of Tissue Distribution and Retention

Hussein¹,

Kassem²,

Elgarhy³

et al. 1967

Isotopenpraxis Isotopes in Environmental and Health Studies

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Part III: Study of Tissue Distribution and Retention

Hussein¹,

Kassem²,

Elgarhy³

et al. 1967

Isotopenpraxis Isotopes in Environmental and Health Studies

View full text Add to dashboard Cite

“…Normal individuals excrete large quantities in the urine following intravenous administration. In leukemic patients radio-phosphorus is probably more quickly fixed in the pathological tissues and cells (3,4).…”

Section: Resultsmentioning

confidence: 99%

Clinical Studies With the Aid of Radioactive Phosphorus. I. The Absorption and Distribution of Radio-Phosphorus in the Blood and Its Excretion by Normal Individuals and Patients With Leukemia 1

Erf¹,

Lawrence²

1941

J. Clin. Invest.

Self Cite

View full text Add to dashboard Cite

The purpose of this paper is (a) to indicate the amount of radio-phosphorus (P32) retained by various fractions of the blood of 4 normal individuals, 12 patients with myeloid, and 15 with lymphoid leukemia, and the variations in retention following the administration of radio-phosphorus when given orally and/or intravenously and when accompanied by varying amounts of non-radioactive phosphorus (P31); (b) to indicate the distribution of pS2 in the bone marrow and in various fractions of white blood cells; and (c) to indicate the amount of radio-phosphorus excreted in urine and feces in these cases. MATERIALS AND METHODSThe radioactive phosphorus was produced by the Berkeley cyclotron (1). The 4 normal individuals were robust, ambulatory workmen with recently healed fractures, all of whom had received the same type and quantity of food over a period of from 1 to 8 weeks, and each of whom had a single regular bowel movement daily during the same period previous to the administration of P'. It was impossible to control the diets or the time of excretion of the patients, all of whom were ambulatory. The blood withdrawn from veins was heparinized, cooled and centrifuged exactly 20 minutes at 1450 times gravity to insure constant volume. The buffy coat was aspirated, suspended in equal amounts of heparinized Ringer's solution and centrifuged exactly 20 minutes at 1450 times gravity. The plasma was then removed from the original tube and finally the red blood cells were extracted. Bone marrow obtained by sternal aspiration was heparinized and centrifuged, as described previously. In some instances, the nuclei were separated from the cytoplasm of the peripheral white blood cells by violent agitation for 20 minutes in cold 5 per cent citric acid (2). The phospholipids were extracted from the white blood cells by the use of ether, alcohol and reflux condensers, and the acid-soluble substances by use of ice-cold 5 per cent trichloracetic acid, thereby leaving 1 These investigations have been aided by a grant from the John and Mary R. Markle Foundation.2Wm. R. Kenan, Jr., Fellow.the nucleoprotein-like substances as residue (3). The assays of radioactivity were made by use of an electrometer.RESULTS

show abstract

“…Within 48 h phosphorus is mainly incorporated into DNA and RNA of dividing cells, partially into phospholipids etc. Later on a predomi nant uptake is found in the bone matrix [14], In this way tissues rich in mitoses, in partic ular growing tumors, are radiolabelled to a greater extent than tissues with a low mitosis rate [3,15]. However, selectivity is not very high.…”

Section: Discussionmentioning

confidence: 99%

“…In the forties, as a result of the rapid development of nuclear research, groups in the United States [3,6,8] and in Germany [11] undertook initial experiments with the radioisotope 32P. The uptake of the radio phosphorus was analyzed with the GeigerMüller counter in animal experiments [4,11] and in operatively excised specimens [5].…”

Section: Historymentioning

confidence: 99%

Topographic Studies with <sup>32</sup>P Tumor Marker during Operations of Brain Tumors

1985

View full text Add to dashboard Cite

A method for the intraoperative detection of brain tumor propagation is described. Based on the well-known radiophosphorus test, a very sensitive semiconductor probe was tested in 16 brain tumor operations. With this miniaturized sensor, the β-emission of ³²P could be measured with a high topographical resolution. Especially in high-grade gliomas, in meningiomas and in metastases a good discrimination of normal and tumor-infiltrated tissue was possible. The perspectives of a technical improvement of this method and the application of more specific tumor markers are discussed.

show abstract

Phosphorus Metabolism in Neoplastic Tissue.

Cited by 24 publications

References 0 publications

Part III: Study of Tissue Distribution and Retention

Part III: Study of Tissue Distribution and Retention

Clinical Studies With the Aid of Radioactive Phosphorus. I. The Absorption and Distribution of Radio-Phosphorus in the Blood and Its Excretion by Normal Individuals and Patients With Leukemia 1

Topographic Studies with <sup>32</sup>P Tumor Marker during Operations of Brain Tumors

Contact Info

Product

Resources

About